Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units
The Pharma Data
AUGUST 17, 2021
An experienced leader in drug development who has led and grown Lilly’s oncology business over the past several years, White will be responsible for Lilly’s launched products and Phase 3 portfolio in pain and neurodegeneration, including the potential launch of donanemab for the treatment of Alzheimer’s disease.
Let's personalize your content